| 1.21 -0.17 (-12.32%) | 12-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.04 |
1-year : | 2.46 |
| Resists | First : | 1.75 |
Second : | 2.1 |
| Pivot price | 1.65 |
|||
| Supports | First : | 1.17 |
Second : | 0.97 |
| MAs | MA(5) : | 1.41 |
MA(20) : | 1.72 |
| MA(100) : | 2 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 5.6 |
D(3) : | 6.9 |
| RSI | RSI(14): 25.1 |
|||
| 52-week | High : | 12.53 | Low : | 1.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ INAB ] has closed below the lower bollinger band by 8.3%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ INAB ] is to continue within current trading range. It is unclear right now based on current values. 65.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.49 - 1.5 | 1.5 - 1.51 |
| Low: | 1.15 - 1.17 | 1.17 - 1.17 |
| Close: | 1.19 - 1.22 | 1.22 - 1.23 |
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Fri, 19 Dec 2025
IN8bio Inc. Stock Surge: Decoding the Unexpected - StocksToTrade
Fri, 19 Dec 2025
IN8bio Signs Multiple Material Agreements - TradingView — Track All Markets
Fri, 19 Dec 2025
IN8bio Secures Up to $40.2 Million in Private Placement to Advance INB-619 and Extend Cash Runway Through 2027 - Quiver Quantitative
Fri, 19 Dec 2025
T cell cancer therapy developer raises $20.1M to push new research - Stock Titan
Tue, 02 Dec 2025
IN8bio Inc. (INAB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Mon, 24 Nov 2025
IN8bio Presents Promising Clinical Trial Results - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 5 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 5.4 (%) |
| Held by Institutions | 21.1 (%) |
| Shares Short | 22 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -5.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.86 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -80.4 % |
| Return on Equity (ttm) | -189.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.24 |
| PEG Ratio | 0 |
| Price to Book value | 0.42 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|